VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Article content

Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market

Article content

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening a significant new market for its NAMkind™ testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human tissue models of the liver and gastrointestinal (GI) tract. The two initial engagements, with a leading Shanghai-based oncology biotech and a large Chengdu-based pharmaceutical company, represent the Company’s first paid programs on the Chinese mainland and a milestone in VivoSim’s expansion across Asia-Pacific.

Article content

Article content

Article content

The two orders cover GI toxicology screening and NAMkind™ GI efficacy profiling for candidate molecules in oncology and other disease areas, and were secured through Tekon, VivoSim’s local distributor in China. Together, the engagements represent a meaningful share of the Company’s contracted revenue to date.

Article content

Article content

“China is now the world’s second-largest pharmaceutical market and among the fastest-moving sources of drug innovation globally, and these first two sales show there is real, paying demand for the human-relevant safety and efficacy data VivoSim is built to deliver,” said Tony Lialin, Chief Commercial Officer of VivoSim. “Landing our first paid programs on the mainland validates our channel strategy and gives us a beachhead to scale a market we believe can become a meaningful contributor to Company revenue.”

Article content

China’s drug regulator, the National Medical Products Administration (NMPA), approved a record 76 innovative drugs in 2025 — up from 48 in 2024 — and the country now accounts for a growing share of the world’s first-in-world drug launches, supported by regulatory reforms that have accelerated development timelines, including a 30-working-day fast-track review channel for eligible innovative-drug clinical trial applications. VivoSim’s internal analysis sizes the addressable China market for liver and gastrointestinal in vitro models and toxicology services at approximately $2 billion, growing at a 10% CAGR. As Chinese regulators and sponsors increasingly evaluate scientifically robust, non-animal evidence, the Company sees a durable tailwind for adoption of its models in the region.

Article content

Article content

VivoSim’s NAMkind™ platform combines 3D human organoid models of the liver and intestine — built from primary human donor cells — with proprietary AI trained on an extensive, real-world dataset. On the same models, VivoSim offers two service lines: toxicology testing, which flags safety liabilities in the liver and GI tract, and efficacy testing, which measures whether a candidate produces its intended biological effect in human-relevant tissue. In toxicology benchmarking against a clinical dataset of 92 small-molecule compounds, the NAMkind™ Liver model achieved 91% predictive accuracy, with 90% sensitivity and 95% specificity — materially outperforming the 50–65% sensitivity typical of animal models and traditional methods. Together, the two service lines help clients screen out toxicity liabilities and confirm efficacy before candidates reach expensive clinical trials, where a single late-stage failure can cost a sponsor years of development time and $50 million to $200 million.

Article content

“The science behind these wins is what makes them repeatable,” said Amar Sethi, MD, PhD, Chief Scientific Officer of VivoSim. “Our multi-endpoint profiling gives development teams in China the same translational signatures we deliver to partners in the U.S. and Europe — the ability to move from detecting liabilities to predicting risk, long before a single patient is dosed.”